Elkfork Partners’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Elkfork Partners’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-164	Closed	-$11K	–	1035
2018 Q1	$11K	Sell	164 -496	-75%	-$35.1K	﹤0.01%	1015
2017 Q4	$48K	Sell	660 -474	-42%	-$39.2K	﹤0.01%	985
2017 Q3	$104K	Sell	1,134 -140	-11%	-$10.7K	﹤0.01%	888
2017 Q2	$84K	Sell	1,274 -425	-25%	-$52.6K	﹤0.01%	903
2017 Q1	$368K	Hold	1,699	–	–	0.01%	506
2016 Q4	$157K	Buy	+1,699	New	+$191K	0.01%	625

Other funds holding LUMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Elkfork Partners's LUMO Position: Q2 2018 in Review

Elkfork Partners sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 164 shares — an estimated $11K sold.

Elkfork Partners first reported a position in LUMO in Q4 2016 and held it in 6 quarters. The position peaked at $368K in Q1 2017. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

Elkfork Partners reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Elkfork Partners sold 164 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $11K.
Elkfork Partners first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2016 and held it in 6 quarters.
Elkfork Partners's Lumos Pharma, Inc. Common Stock position peaked at $368K in Q1 2017.
106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on Elkfork Partners's 13F filing for Q2 2018, filed 14 Aug 2018.